

June 21, 2021

Dear Shareholders

Christophe Weber
President and Representative Director
Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome
Chuo-ku, Osaka

Partial Correction to the Notice of Convocation of the 145th Ordinary General Meeting
of Shareholders

Takeda Pharmaceutical Company Limited (the “Company”) hereby reports that there are parts to be corrected in the Notice of Convocation of the 145th Ordinary General Meeting of Shareholders (the “Notice”) and that the Company therefore decided to make a correction to the said parts as described herein below.

1. Correction parts:

Mr. Christophe Weber (President and Representative Director of the Company)’s title at Takeda Pharmaceuticals U.S.A., Inc. where he concurrently serves, which is mentioned in the Third Proposal (page 11) and the Fifth Proposal (page 27) in the “Reference Document for the General Meeting of Shareholders” of the Notice, and in the Section 3. (1) (page 68) of the Business Report enclosed with the Notice

2. Contents of the correction:

Before correction	After correction
<u>Executive Chairman</u>	<u>Head of Global Business</u>

[End of document]